$13.5
Revenue is down for the last 2 quarters, 36.34M → 33.44M (in $), with an average decrease of 8.0% per quarter
Netprofit is down for the last 3 quarters, -43.04M → -45.96M (in $), with an average decrease of 3.4% per quarter
In the last 3 years, Deciphera Pharmaceuticals Inc has experienced a drawdown of -76.8%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 49.0%
0.81%
Downside
Day's Volatility :5.7%
Upside
4.93%
24.89%
Downside
52 Weeks Volatility :55.45%
Upside
40.69%
Period | Deciphera Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.21% | -0.3% | -6.7% |
6 Months | -14.52% | -8.8% | -6.2% |
1 Year | 25.46% | -4.2% | -5.1% |
3 Years | -77.59% | 23.0% | 26.9% |
Market Capitalization | 1.1B |
Book Value | $5.61 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.07 |
Wall Street Target Price | 21.33 |
Profit Margin | -131.38% |
Operating Margin TTM | -136.76% |
Return On Assets TTM | -25.29% |
Return On Equity TTM | -51.05% |
Revenue TTM | 138.3M |
Revenue Per Share TTM | 1.7 |
Quarterly Revenue Growth YOY | 14.399999999999999% |
Gross Profit TTM | -62.6M |
EBITDA | -186.3M |
Diluted Eps TTM | -2.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.46 |
EPS Estimate Next Year | -2.04 |
EPS Estimate Current Quarter | -0.59 |
EPS Estimate Next Quarter | -0.58 |
What analysts predicted
Upside of 58.0%
Sell
Neutral
Buy
Deciphera Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Deciphera Pharmaceuticals, Inc. | -6.01% | -14.52% | 25.46% | -77.59% | -47.12% |
![]() Neurocrine Biosciences Inc. | -13.37% | -29.08% | -3.62% | -26.98% | -6.39% |
![]() Zoetis Inc. | -10.37% | 4.41% | -5.84% | 16.34% | 92.28% |
![]() Viatris Inc. | -1.92% | -16.77% | -25.18% | -43.82% | -43.82% |
![]() Catalent, Inc. | -27.33% | -27.35% | -64.66% | -52.48% | -7.23% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Deciphera Pharmaceuticals, Inc. | NA | NA | NA | -2.46 | -0.51 | -0.25 | 0.0 | 5.61 |
![]() Neurocrine Biosciences Inc. | 147.13 | 147.13 | 1.87 | 2.1 | 0.04 | 0.08 | 0.0 | 17.28 |
![]() Zoetis Inc. | 37.27 | 37.27 | 3.53 | 5.4 | 0.45 | 0.13 | 0.01 | 9.72 |
![]() Viatris Inc. | 5.82 | 5.82 | NA | 2.95 | 0.09 | 0.03 | 0.05 | 17.45 |
![]() Catalent, Inc. | 16.09 | 16.09 | 1.18 | 1.37 | 0.09 | 0.04 | 0.0 | 27.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Deciphera Pharmaceuticals, Inc. | Buy | $1.1B | -47.12% | NA | -131.38% |
![]() Neurocrine Biosciences Inc. | Buy | $8.9B | -6.39% | 147.13 | 4.0% |
![]() Zoetis Inc. | Buy | $76.1B | 92.28% | 37.27 | 25.59% |
![]() Viatris Inc. | Hold | $10.9B | -43.82% | 5.82 | 12.05% |
![]() Catalent, Inc. | Buy | $6.6B | -7.23% | 16.09 | 8.62% |
Redmile Group, LLC
BlackRock Inc
Deerfield Management Co
Vanguard Group Inc
Armistice Capital, LLC
State Street Corporation
Deciphera Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read MoreDeciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Organization | Deciphera Pharmaceuticals, Inc. |
Employees | 300 |
CEO | Mr. Steven L. Hoerter |
Industry | Health Technology |
WisdomTree US AI Enhanced Value Fund
$87.78
-0.41%
HOOKIPA Pharma Inc.
$1.31
-5.76%
BLACKROCK MUNIYIELD QUAL II
$9.91
-0.2%
LUTHER BURBANK CORP
$8.60
-2.49%
Market Vectors Biotech ETF
$154.74
-0.08%
NOW Inc.
$8.89
-4.1%
Central Garden & Pet Co A Shares
$34.35
-0.95%
FARMERS & MERCHANTS BANCO/OH
$19.89
-2.98%
ISHARES GOLD TRUST MICRO
$19.61
+0.18%